MAPT and Alzheimer disease: Preliminary studies investigating the tau ligand 18F-AV-1451 have indicated increased binding of 18F-AV-1451 in the medial temporal lobe can distinguish AD from probable DLB patients [23], and elevated cortical binding of 18F-AV-1451 to tau in DLB patients is associated with a decline in cognition [24].